Blog
About

16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Triptolide reduces prostate size and androgen level on testosterone-induced benign prostatic hyperplasia in Sprague Dawley rats

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Benign prostatic hyperplasia (BPH) is an age-related disease of unknown etiology, characterized by prostatic enlargement coincident with distinct alterations in tissue histology. In the present study, we investigated whether triptolide can prevent testosterone-induced prostatic hyperplasia in rats. Castration was performed via the scrotal route after urethane aesthesia. BPH was induced in experimental groups by daily subcutaneous injections of testosterone propionate (TP) for two weeks. Triptolide was administered daily by oral gavage at a dose of 100 and 50 μg·kg −1 for 2 weeks, along with the TP injections. On day 14, the animals were humanely killed by cervical dislocation after aesthesia. Prostates were excised, weighed, and used for histological studies. Testosterone and dihydrotestosterone (DHT) levels in serum and prostate were measured. The results showed that triptolide significantly reduced the prostate weight, and the testosterone and DHT levels in both the serum and prostate. Histopathological examination also showed that triptolide treatment suppressed TP-induced prostatic hyperplasia. In conclusion, triptolide effectively inhibits the development of BPH induced by testosterone in a rat model.

          Related collections

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier
          1875-5364
          20 May 2017
          : 15
          : 5
          : 341-346
          Affiliations
          1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
          2Center for Molecular Metabolism, School of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210014, China
          3Jiangsu Key Laboratory of Drug Screening and Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China
          4Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 210009, China
          Author notes
          *Corresponding author: ZHANG Lu-Yong, Tel: 86-25-83271340, Fax: 86-25-83271142, E-mail: lyzhang@ 123456cpu.edu.cn ; WANG Tao, Tel: 86-25-83271043, Fax: 86-25-83271142; E-mail: wangtao1331@ 123456126.com

          ΔThese authors contributed to this work equally.

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(17)30054-7
          10.1016/S1875-5364(17)30054-7
          28558869
          Copyright © 2017 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          Funding
          Funded by: National Natural Science Foundation of China
          Award ID: 81173651
          Award ID: 81320108029
          Award ID: 81303301
          This work was supported by National Natural Science Foundation of China (Nos. 81173651, 81320108029, and 81303301) and the 2011’ Program for Excellent Scientific and Technological Innovation Team of Jiangsu Higher Education, “the 111 Project (111-2-07)”.

          Comments

          Comment on this article